AT1 FY21 - General Discussion + FA, page-1319

But the big question is: will it show up on the revenue (invoiced) and/or cash receipt (invoice paid) this Q or next Q or next year... or does it sit in limbo until FDA approval happens, and if FDA approval never happens then the sale never happens.

Re the rapid covid blood test agreement with AccessBio (I think 1 mill units) I thought that would replace, offset the NGBiotech stop (they took 900k last year). But I dont understand what is up with that. Why are sales and cash receipts diving?

You get the feeling Atomo is like a dam, ready to burst forth (in a good way). We really appreciate the container updates. It gives us hope. At some stage this will turn, but who know when. The key now is picking a bottom (if you are game to add some more poker chips onto the table... should us investors fold, call, or go all in!)